Rhythm Pharmaceuticals EMANATE Phase 3 Misses Primary Endpoint, Sees Subgroup Signals for Setmelanotide [Yahoo! Finance]
Rhythm Pharmaceuticals, Inc. (RYTM)
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rhythmtx.com
Company Research
Source: Yahoo! Finance
weeks) across all four genetic cohorts, and management said it will not seek regulatory filings or run additional setmelanotide trials in these indications. Post-hoc and subgroup analyses suggested activity in POMC heterozygous and SRC1 populations—some LOCF analyses showed placebo-adjusted differences up to ~12.7% in small subsets—but these signals are limited by high discontinuation rates, evolving variant classification, and the post-hoc nature of the analyses. Rhythm will pivot to next-generation therapies and refine genetic testing and trial execution, prioritizing hypothalamic obesity, Prader-Willi, Bardet-Biedl studies and patients with confirmed loss-of-function variants. Interested in Rhythm Pharmaceuticals, Inc.? Here are five stocks we like better. 7 Stocks That Will Drive the Weight Loss Drugs Market Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Phase 3 top-line results from its EMANATE trial evaluating setmelanotide in four heterozygous genetic cohorts linked to
Show less
Read more
Impact Snapshot
Event Time:
RYTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RYTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RYTM alerts
High impacting Rhythm Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RYTM
News
- How Investors May Respond To Rhythm Pharmaceuticals (RYTM) FDA Win For IMCIVREE In Acquired Hypothalamic Obesity [Yahoo! Finance]Yahoo! Finance
- Rhythm Pharmaceuticals Wins FDA Approval for IMCIVREE in Acquired Hypothalamic Obesity Launch [Yahoo! Finance]Yahoo! Finance
- Rhythm obesity drug wins broader use from FDA [Yahoo! Finance]Yahoo! Finance
- PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)PR Newswire
- Rhythm Pharmaceuticals (RYTM) Reports Phase 3 EMANATE Trial Topline Results for Setmelanotide [Yahoo! Finance]Yahoo! Finance
RYTM
Earnings
- 2/26/26 - Beat
RYTM
Sec Filings
- 3/20/26 - Form 8-K
- 3/16/26 - Form 8-K
- 3/16/26 - Form 4
- RYTM's page on the SEC website